Open Access Helper

OpenAlex Citation Counts

OpenAlex Citations Logo

OpenAlex is a bibliographic catalogue of scientific papers, authors and institutions accessible in open access mode, named after the Library of Alexandria. It's citation coverage is excellent and I hope you will find utility in this listing of citing articles!

If you click the article title, you'll navigate to the article, as listed in CrossRef. If you click the Open Access links, you'll navigate to the "best Open Access location". Clicking the citation count will open this listing for that article. Lastly at the bottom of the page, you'll find basic pagination options.

Requested Article:

Immunotherapy vs Best Supportive Care for Patients With Hepatocellular Cancer With Child-Pugh B Dysfunction
Claudia Angela Maria Fulgenzi, Bernhard Scheiner, Antonio D’Alessio, et al.
JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1253-1253
Closed Access | Times Cited: 10

Showing 10 citing articles:

Cirrhosis and complications hepatocellular carcinoma – expanding indications for immunotherapy
Helena Degroote
Acta Clinica Belgica (2025), pp. 1-7
Closed Access
Systemic therapy for child-pugh B patients with hepatocellular carcinoma
Kevin Mok, Olivia Chen, Johnny Yau, et al.
Expert Opinion on Emerging Drugs (2025), pp. 1-5
Closed Access
Efficacy of atezolizumab plus bevacizumab for unresectable HCC: systematic review and metanalysis of real-world evidence
Giulia Francesca Manfredi, Claudia Angela Maria Fulgenzi, Ciro Celsa, et al.
JHEP Reports (2025), pp. 101431-101431
Open Access
Systemic treatment in patients with hepatocellular carcinoma and advanced liver dysfunction
Matthias Pinter, Claudia Angela Maria Fulgenzi, David J. Pinato, et al.
Gut (2025), pp. gutjnl-334928
Closed Access
Comparative efficacy of interventional therapy with or without targeted immunotherapy in Child-Pugh B hepatocellular carcinoma patients: a single-center, retrospective study
Xufeng Guo, Man Zhao, Xiaoling Duan, et al.
Frontiers in Oncology (2025) Vol. 15
Open Access
CRAFITY score and nomogram predict the clinical efficacy of lenvatinib combined with immune checkpoint inhibitors in hepatocellular carcinoma
Xue Yin, Na Deng, Xiaoyan Ding, et al.
World Journal of Gastroenterology (2025) Vol. 31, Iss. 7
Closed Access
Future perspectives on immunotherapy for hepatocellular carcinoma
Landon L. Chan, Stephen L. Chan
Therapeutic Advances in Medical Oncology (2025) Vol. 17
Open Access
Soluble Urokinase Plasminogen Activator Receptor Predicts Survival and Hepatic Decompensation in Advanced Hepatocellular Carcinoma
Fabian Jost‐Brinkmann, Sven Lamatsch, Minh D. Phan, et al.
Liver International (2025) Vol. 45, Iss. 6
Open Access
Error in Figure 1

JAMA Oncology (2024) Vol. 10, Iss. 9, pp. 1294-1294
Closed Access
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction
Calum Polwart
JAMA Oncology (2024)
Closed Access
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction
Manuel David Gil-Sierra, María Del Pilar Briceño-Casado, Cristina Moreno-Ramos
JAMA Oncology (2024)
Closed Access
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction
Yasuyuki Shigematsu
JAMA Oncology (2024)
Closed Access
Immunotherapy Benefit Over Best Supportive Care in Hepatocellular Cancer With Child-Pugh B Dysfunction—Reply
Claudia Angela Maria Fulgenzi, Antonio D’Alessio, David J. Pinato
JAMA Oncology (2024)
Closed Access
Page 1

Scroll to top